SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma Research Published on 2021-03-022022-10-05 Journal: Nature Medicine [Category] SARS, 치료기술, 치료법, [키워드] 501Y.V2 African antibodies B.1.351 binding Complete convalescent plasma coronavirus COVID-19 domain Donor Efficacy exhibit expressing highlight immunodominant neutralization novel lineage plasma pseudovirus reduced Reinfection SARS-CoV-2 South Spike protein spike-based vaccines Substitution the spike protein variant [DOI] 10.1038/s41591-021-01285-x [Article Type] Research
Detection of B.1.351 SARS-CoV-2 Variant Strain — Zambia, December 2020B.1.351 SARS-CoV-2 변종 균주 검출 — 잠비아, 2020년 12월Full Report Published on 2021-02-262022-09-10 Journal: Morbidity and Mortality Weekly Report [Category] MERS, 변종, 치료기술, [키워드] B.1.351 detection SARS-CoV-2 strain [DOI] 10.15585/mmwr.mm7008e2 PMC 바로가기 [Article Type] Full Report
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoVSARS-CoV-2 및 SARS-CoV 모두에 대해 교차 중화 활성을 갖는 인간 단일클론 항체인 MW06의 특성화Article Published on 2021-01-012022-09-11 Journal: mAbs [Category] 변종, 진단, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition ADE alignment angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 anti-SARS-CoV-2 antibody antibody-based therapy Antibody-dependent enhancement antibody-dependent enhancement (ADE) assays authorization B.1.1.7 B.1.351 B.1.617.1 bind caused characterization clinical trial cocktail complex conserved coronavirus coronavirus strains COVID-19 cross-neutralization activity cross-reactive demonstrated disrupt Effect effective effective interventions Emergency use epitope global pandemic Human monoclonal antibody in vitro assays Interaction Intervention mAb mAbs monoclonal antibody mutations neutralization neutralization activity neutralizing monoclonal antibodies P.1 Phase 2 Potential Prevent Prophylactic provide RBD receptors recognize respiratory SARS-CoV SARS-CoV-2 SARS-COV-2 infection SARS-related coronavirus severe acute respiratory syndrome Coronavirus spike receptor-binding domain Strains therapeutic efficacy Treatment treatment of COVID-19 variant variants variants of concern widespread [DOI] 10.1080/19420862.2021.1953683 PMC 바로가기 [Article Type] Article
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351붉은 털 원숭이에서 SARS-CoV-2에 대한 강력한 효능의 인간 항체는 B.1.351에 대한 강력한 차단 활성을 나타냈습니다Article Published on 2021-01-012022-09-11 Journal: mAbs [Category] MERS, 변종, 진단, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibody B.1.1.7 B.1.351 binding blocking activity broad-spectrum cause clinical trial Complete convalescent plasma coronavirus coronavirus disease coronavirus disease-2019 Coronavirus-2 COVID-19 COVID-19 pandemic D614G demonstrated disease Efficacy hACE2 host cell host cell receptor in vitro Infection interact Intervention JMB2002 lead neutralization Neutralizing Neutralizing antibodies neutralizing antibody phage phage-to-yeast Phase 1 Phase 1 clinical trial platform Prophylactic Protein RBD Receptor binding domain respiratory rhesus rhesus macaque rhesus macaque disease model. SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sequence sera Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 the RBD the SARS-CoV-2 therapeutic therapeutic efficacy Transmission Vaccine virus yeast [DOI] 10.1080/19420862.2021.1930636 PMC 바로가기 [Article Type] Article